180 related articles for article (PubMed ID: 30275227)
1. Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
Anticancer Res; 2018 Oct; 38(10):5969-5974. PubMed ID: 30275227
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
Anticancer Res; 2018 Oct; 38(10):5975-5981. PubMed ID: 30275228
[TBL] [Abstract][Full Text] [Related]
3. [Combination Chemotherapy Including Intraperitoneal(IP)Administration of Paclitaxel(PTX)followed by PTX, CDDP and S-1Triplet Chemotherapy for CY1P0 Gastric Cancer].
Shinkai M; Imano M; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Kimura Y; Imamoto H; Furukawa H; Yasuda T
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1355-1357. PubMed ID: 29394632
[TBL] [Abstract][Full Text] [Related]
4. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J
Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.
Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Emoto S; Kitayama J; Ishigami H; Yamaguchi H; Watanabe T
Ann Surg Oncol; 2015 Mar; 22(3):780-6. PubMed ID: 25216603
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
[TBL] [Abstract][Full Text] [Related]
8. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
Kanazawa Y; Kato S; Fujita I; Onodera H; Uchida E
J Nippon Med Sch; 2013; 80(5):378-83. PubMed ID: 24189356
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer.
Peng YF; Imano M; Itoh T; Satoh T; Chiba Y; Imamoto H; Tsubaki M; Nishida S; Yasuda T; Furukawa H
J Surg Oncol; 2015 Jun; 111(8):1041-6. PubMed ID: 26060133
[TBL] [Abstract][Full Text] [Related]
12. [Treatment for advanced gastric cancer with positive lavage cytology-systemic versus intraperitoneal chemotherapy].
Iwasaki Y; Ohashi M; Nunobe S; Iwanaga T; Iwagami S; Takahashi K; Yamaguchi T; Matsumoto H; Nakano D
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2009-11. PubMed ID: 19106506
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
Yamaguchi T; Takashima A; Nagashima K; Makuuchi R; Aizawa M; Ohashi M; Tashiro K; Yamada T; Kinoshita T; Hata H; Kawachi Y; Kawabata R; Tsuji T; Hihara J; Sakamoto T; Fukagawa T; Katai H; Higuchi K; Boku N
Ann Surg Oncol; 2020 Jan; 27(1):284-292. PubMed ID: 31535301
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H
Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.
Tamura S; Miki H; Okada K; Miyake T; Yoshimura M; Suzuki R; Nakahira S; Nakata K; Okamura S; Sugimoto K; Takatsuka Y
Int J Clin Oncol; 2008 Dec; 13(6):536-40. PubMed ID: 19093182
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
18. [A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy].
Asami S; Idani H; Kubo S; Sasaki H; Kurose Y; Nojima H; Yoshioka T; Muro M; Kumano K; Hirata M; Yamashita T; Kin H; Takakura N
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2287-9. PubMed ID: 20037398
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Yamaguchi H; Satoh Y; Ishigami H; Kurihara M; Yatomi Y; Kitayama J
Ann Surg Oncol; 2017 Oct; 24(11):3345-3352. PubMed ID: 28726078
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
